submit to the journals

Multiple Myeloma Journal Articles, Videos And Insights

Multiple Myeloma:FEATURED Articles

flipper_slider

Multiple Myeloma: INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Meeting Proceedings
New Combined Treatment Options for Relapsed/Refractory Multiple Myeloma – The OPTIMISMM Study Katrina Mountfort, Senior Medical Writer, Touch Medical Media, UK
Tim Sheldrick, Account Director and Advisory Editor, Touch Medical Media, UK

Multiple Myeloma:FEATURED VIDEOS

Editor's choice

Paul Richardson from the Dana-Farber Cancer Institute and Harvard Medical School provides an overview of the key findings of the OPTIMISMM trial and discusses the need for new treatment strategies in multiple myeloma. 1. Why is there a need for new combinations of therapies in relapsed/refractory multiple myeloma? (0:09) 2. Could you tell us a little about the study design and what doses were used? (2:51) 3. What were the efficacy and safety findings of the combination? (4:22) 4. What other combined therapies are being considered for future studies? (5:10) Speaker disclosures: Paul Richardson has nothing to disclose in relation to this video interview. Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018
We catch up with our US Editor-in-Chief to discuss advances in molecular targets and treatment in multiple myeloma, as well as important updates in the latest NCCN guidelines. 1. What do you consider the most important unmet needs in the treatment of multiple myeloma? (0:11) 2. What are the most important emerging molecular targets in the treatment of multiple myeloma? (1:14) 3. What new treatment approaches do you expect to emerge in coming years? (3:51) 4. What therapies have become available for patients with relapsed/refractory disease? (4:32) 5. What are the most important updates and changes in the latest NCCN Guidelines for multiple myeloma? (5:33) Speaker disclosures: Shaji Kumar has nothing to disclose in relation to this video interview. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018

Multiple Myeloma:Latest Videos

Video List based on Category on Node Page

Latest Videos

Paul Richardson from the Dana-Farber Cancer Institute and Harvard Medical School provides an overview of the key findings of the OPTIMISMM trial and discusses the need for new treatment strategies in multiple myeloma. 1. Why is there a need for new combinations of therapies in...
Muzaffar Qazilbash from The University of Texas MD Anderson Cancer Center talks to touchONCOLOGY about investigating busulfan plus melphalan as a potential combination therapy for high-risk multiple myeloma. 1. What was the rationale for using a combined busulfan and melphalan...
We catch up with our US Editor-in-Chief to discuss advances in molecular targets and treatment in multiple myeloma, as well as important updates in the latest NCCN guidelines. 1. What do you consider the most important unmet needs in the treatment of multiple myeloma? (0:11) 2. What...
James B Bussel talks about the unmet needs in the treatment of adult and pediatric ITP, and the recent finding of fostamatinib in adult persistent/chronic ITP.
Oncology & Hematology Review's Editor-in-Chief Shaji Kumar discusses his highlights from ASH 2017 and the most exciting developments in myeloma to look out for in 2018.
Dr Shaji Kumar reviews the rationale for targeting the BCL-2 protein in multiple myeloma (MM) and the results of the recent phase I study of venetoclax. He also discusses selinexor combination therapy and the role of minimal residual disease in assessing response to therapies. FILMED AT THE...

LATEST TWEETS

Conference Highlights